热门资讯> 正文

Cybin报告第一季度业绩

2026-08-14 19:31

Intra-Cellular Therapies(ITCI) 0

Cybin press release (HELP): Q1 Net loss was $47.8 million for the quarter ended June 30, 2026, compared to a net loss of $24.6 million in the same period last year.
Cash totaled $166.4 million as of June 30, 2026.
Cash-based operating expenses consisting of research, general, and administrative costs totaled $37.5 million for the quarter ended June 30, 2026, compared to $23.9 million, in the same period last year.

More on Cybin

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
Cybin: A Speculative Bet On Their Pivotal Depression Readout
Cybin continues rally following CEO appointment, up another 13%
Helus Pharma names ex-Intra-Cellular executive Michael Halstead as CEO
Seeking Alpha’s Quant Rating on Cybin

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。